1 – 20 of 33
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Prognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer
(
- Contribution to journal › Article
- 2019
-
Mark
Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities : further results from the prospective PANTHER study with focus on obese patients
2019) In Annals of oncology : official journal of the European Society for Medical Oncology 30(1). p.109-114(
- Contribution to journal › Article
- 2018
-
Mark
A randomised study of tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy for early breast cancer (SBG 2000-1)
(
- Contribution to journal › Article
- 2017
-
Mark
High expression of stromal PDGFRβ is associated with reduced benefit of tamoxifen in breast cancer
(
- Contribution to journal › Article
- 2015
-
Mark
Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival
(
- Contribution to journal › Article
- 2014
-
Mark
Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events
(
- Contribution to journal › Article
-
Mark
Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial
(
- Contribution to journal › Article
- 2013
-
Mark
Angiogenic factors in relation to clinical effect in a phase II trial of weekly paclitaxel
(
- Contribution to journal › Article
-
Mark
Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial
(
- Contribution to journal › Article
- 2012
-
Mark
Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial
(
- Contribution to journal › Article
- 2011
-
Mark
Growth and carbon sequestration by ectomycorrhizal fungi in intensively fertilized Norway spruce forests
(
- Contribution to journal › Article
- 2010
-
Mark
STROMA-DERIVED MARKERS PREDICTING BREAST CANCER PROGNOSIS AND TREATMENT RESPONSE
(
- Contribution to journal › Published meeting abstract
- 2009
-
Mark
First Results from FACT - An Open-Label, Randomized Phase III Study Investigating Loading Dose of Fulvestrant Combined with Anastrozole Versus Anastrozole at First Relapse in Hormone Receptor Positive Breast Cancer
(
- Contribution to journal › Published meeting abstract
- 2008
-
Mark
A randomized feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer
2008) EBCC-6, European Breast Cancer Conference, 2008 In European Journal of Cancer Supplements 6(7). p.116-117(
- Contribution to journal › Published meeting abstract
- 2007
-
Mark
Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy
(
- Contribution to journal › Article
- 2006
-
Mark
Time dependent effects of tamoxifen treatment on cardiovascular morbidity
(
- Contribution to journal › Published meeting abstract
- 2005
-
Mark
Topoisomerase IIa gene amplification predicts favorable outcome of tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2 positive breast cancer. Results from the randomized trial SBG 9401.
(
- Contribution to journal › Published meeting abstract
-
Mark
Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: Results from a randomized trial
(
- Contribution to journal › Article
-
Mark
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
(
- Contribution to journal › Article
- 2004
-
Mark
Overexpression of cyclin E protein is associated with specific mutation types in the p53 gene and poor survival in human breast cancer
(
- Contribution to journal › Article